<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084266</url>
  </required_header>
  <id_info>
    <org_study_id>A5951001</org_study_id>
    <nct_id>NCT00084266</nct_id>
  </id_info>
  <brief_title>Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)</brief_title>
  <acronym>ZEPHYR</acronym>
  <official_title>Linezolid In The Treatment Of Subjects With Nosocomial Pneumonia Proven To Be Due To Methicillin-Resistant Staphylococcus Aureus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired
      in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult
      subjects. Subjects entered in to the study will have proven healthcare-associated
      methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either
      linezolid or vancomycin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population</measure>
    <time_frame>EOS (7-30 days after last dose)</time_frame>
    <description>Clinical response was based primarily on global assessment of clinical presentation of participant made by investigator at evaluation timepoint. Clinical response was evaluated at EOS Visit as Cure: resolution of clinical signs/symptoms of pneumonia when compared with baseline; Failure: persistence/progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection; Unknown:extenuating circumstances precluding classification to 1 of the above.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome in Participants With Baseline MRSA at EOS for mITT Population</measure>
    <time_frame>EOS (7-30 days after last dose)</time_frame>
    <description>Clinical response was based primarily on global assessment of clinical presentation of participant made by investigator at evaluation timepoint. Clinical response was evaluated at EOS Visit as Cure: resolution of clinical signs/symptoms of pneumonia when compared with baseline; Failure: persistence/progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection; Unknown:extenuating circumstances precluding classification to 1 of the above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome in Participants With Baseline MRSA at End of Treatment (EOT) for PP Population</measure>
    <time_frame>EOT (within 72 hours of last dose)</time_frame>
    <description>Clinical response evaluated at EOT visit as Cure:resolution of clinical sign/symptoms of pneumonia when compared with baseline;Improvement: in 2 or more clinical sign/symptoms of pneumonia when compared with baseline,improvement/lack of progression of all chest X-ray abnormalities,Failure: persistence/ progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection;Unknown: extenuating circumstances precluding classification to 1 of above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome in Participants With Baseline MRSA at EOT for mITT Population</measure>
    <time_frame>EOT (within 72 hours of last dose)</time_frame>
    <description>Clinical response evaluated at EOT visit as Cure:resolution of clinical sign/symptoms of pneumonia when compared with baseline;Improvement: in 2 or more clinical sign/symptoms of pneumonia when compared with baseline,improvement/lack of progression of all chest X-ray abnormalities,Failure: persistence/ progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection;Unknown: extenuating circumstances precluding classification to 1 of above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome in Participants With Baseline MRSA at EOS for PP Population</measure>
    <time_frame>EOS (7-30 days after last dose)</time_frame>
    <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome in Participants With Baseline MRSA at EOS for mITT Population</measure>
    <time_frame>EOS (7-30 days after last dose)</time_frame>
    <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome in Participants With Baseline MRSA at EOT for PP Population</measure>
    <time_frame>EOT (within 72 hours of last dose)</time_frame>
    <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome in Participants With Baseline MRSA at EOT for mITT Population</measure>
    <time_frame>EOT (within 72 hours of last dose)</time_frame>
    <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Signs and Symptoms at EOS for PP Population</measure>
    <time_frame>EOS (7-30 days after last dose)</time_frame>
    <description>Participant's clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Signs and Symptoms at EOS for mITT Population</measure>
    <time_frame>EOS (7-30 days after last dose)</time_frame>
    <description>Participant's clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Signs and Symptoms at EOT for PP Population</measure>
    <time_frame>EOT (within 72 hours of last dose)</time_frame>
    <description>Participant's clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Signs and Symptoms at EOT for mITT Population</measure>
    <time_frame>EOT (within 72 hours of last dose)</time_frame>
    <description>Participant's clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Status Estimated by Kaplan-Meier Analysis for PP Population</measure>
    <time_frame>From baseline until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose.</time_frame>
    <description>For each participant, time to death was estimated from baseline to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose. The distribution of survival was estimated for the treatment groups using the Kaplan-Meier, product-limit method and compared between the treatment groups using the log rank statistic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Status Estimated by Kaplan-Meier Analysis for mITT Population</measure>
    <time_frame>From baseline until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose.</time_frame>
    <description>For each participant, time to death was estimated from baseline to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose. The distribution of survival was estimated for the treatment groups using the Kaplan-Meier, product-limit method and compared between the treatment groups using the log rank statistic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Status Estimated by Kaplan-Meier Analysis for ITT Population</measure>
    <time_frame>From baseline until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose.</time_frame>
    <description>For each participant, time to death was estimated from baseline to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose. The distribution of survival was estimated for the treatment groups using the Kaplan-Meier, product-limit method and compared between the treatment groups using the log rank statistic.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1225</enrollment>
  <condition>Methicillin Resistant Staphylococcus Aureus (MRSA)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving linezolid for the treatment phase of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects receiving vancomycin for the treatment phase of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linezolid (Zyvox)</intervention_name>
    <description>Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zyvox, linezolid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vancomycin</intervention_name>
    <description>Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized male and female subjects with clinically documented nosocomial pneumonia
             proven to be due to methicillin-resistant staphylococcus aureus.

          -  Chest X-ray at baseline/screen or within 48 hours of treatment consistent with the
             diagnosis of pneumonia.

          -  Suitable sputum specimen defined as having less than 10 squamous epithelial cells and
             greater or equal 25 leukocytes or have a culture taken by an invasive technique within
             24 hours of study entry.

        Exclusion Criteria:

          -  Subjects who were treated with a previous antibiotic with MRSA activity (other than
             linezolid or vancomycin) for more than 48 hours, unless documented to be a treatment
             failure (72 hours of treatment and not responding).

          -  Subjects with severe neutropenia (&lt;500 cells/mm3)

          -  Subjects with hypersensitivity to oxazolidinones or vancomycin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60302-2566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47151</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Loius</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-9800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-8410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-7110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-1608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Marcos</city>
        <state>Texas</state>
        <zip>78666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sequin</city>
        <state>Texas</state>
        <zip>78155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1181</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liege 1</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>40420-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Región Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bogota</city>
        <state>Bogota. DC</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ibague</city>
        <state>Tolima</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <state>Cedex 18</state>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint Etienne Cedex 02</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kifisia</city>
        <state>Athens</state>
        <zip>14561</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>134-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Monterrey/Col. Mitras Centro</city>
        <state>Nuevo Léon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ciudad Madero</city>
        <state>Tamaulipas</state>
        <zip>89440</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31 - 066</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-066</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Almada</city>
        <zip>2800</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3041</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1449-005</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Senhora da Hora</city>
        <zip>4464-513</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00921-3201</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <state>Russia</state>
        <zip>117049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>113093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115446</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>123448</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Auckland Park</city>
        <zip>2006</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bloefontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pan-Chiao</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Venezuela</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5951001&amp;StudyName=Nosocomial%20Pneumonia%20With%20Suspected%20Or%20Proven%20Methicillin-Resistant%20Staphylococcus%20Aureus%20%28MRSA%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <results_first_submitted>March 10, 2011</results_first_submitted>
  <results_first_submitted_qc>April 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2011</results_first_posted>
  <last_update_submitted>January 30, 2012</last_update_submitted>
  <last_update_submitted_qc>January 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staphylococcal pneumonia</keyword>
  <keyword>Methicillin-resistant staphylococcal pneumonia</keyword>
  <keyword>healthcare-associated pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Methicillin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Linezolid</title>
          <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
        </group>
        <group group_id="P2">
          <title>Vancomycin</title>
          <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="618"/>
                <participants group_id="P2" count="607"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="597"/>
                <participants group_id="P2" count="587"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="441"/>
                <participants group_id="P2" count="423"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant not willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="360"/>
                <participants group_id="P2" count="344"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized not treated</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Linezolid</title>
          <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
        </group>
        <group group_id="B2">
          <title>Vancomycin</title>
          <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="597"/>
            <count group_id="B2" value="587"/>
            <count group_id="B3" value="1184"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" spread="18.4"/>
                    <measurement group_id="B2" value="60.5" spread="18.4"/>
                    <measurement group_id="B3" value="60.5" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="395"/>
                    <measurement group_id="B2" value="380"/>
                    <measurement group_id="B3" value="775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Signs and Symptoms for modified intent-to-treat (mITT) Population</title>
          <description>Clinical signs and symptoms (mild to severe):cough;production of purulent sputum;auscultatory finding on pulmonary examination of rales,pulmonary consolidation(dullness on percussion, bronchial breath sounds,egophony);dyspnea, tachypnea,hypoxemia with partial pressure of oxygen(PaO2)&lt;60 mmHg/worsening gas exchange/increased O2 requirement.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Decreased Breath Sounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoxia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Consolidation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rales</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachypnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills/Rigors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleuritic Chest Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Purulent Sputum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Signs and Symptoms for Per Protocol (PP) Population</title>
          <description>Clinical signs and symptoms (mild to severe):cough;production of purulent sputum;auscultatory finding on pulmonary examination of rales,pulmonary consolidation(dullness on percussion, bronchial breath sounds,egophony);dyspnea, tachypnea,hypoxemia with PaO2&lt;60 mmHg/worsening gas exchange/increased O2 requirement.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Decreased Breath Sounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoxia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Consolidation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rales</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachypnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills/Rigors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleuritic Chest Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Purulent Sputum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population</title>
        <description>Clinical response was based primarily on global assessment of clinical presentation of participant made by investigator at evaluation timepoint. Clinical response was evaluated at EOS Visit as Cure: resolution of clinical signs/symptoms of pneumonia when compared with baseline; Failure: persistence/progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection; Unknown:extenuating circumstances precluding classification to 1 of the above.</description>
        <time_frame>EOS (7-30 days after last dose)</time_frame>
        <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure) and had observed outcome for that visit unless already declared failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population</title>
          <description>Clinical response was based primarily on global assessment of clinical presentation of participant made by investigator at evaluation timepoint. Clinical response was evaluated at EOS Visit as Cure: resolution of clinical signs/symptoms of pneumonia when compared with baseline; Failure: persistence/progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection; Unknown:extenuating circumstances precluding classification to 1 of the above.</description>
          <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure) and had observed outcome for that visit unless already declared failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Missing (excluded from analysis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chi-squared test was used to calculate p-value. P-value was calculated for participants with clinical outcome as &quot;cure&quot;.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The final p-value was compared against an O'Brien-Fleming boundary of 0.048.</non_inferiority_desc>
            <p_value>0.042</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome in Participants With Baseline MRSA at EOS for mITT Population</title>
        <description>Clinical response was based primarily on global assessment of clinical presentation of participant made by investigator at evaluation timepoint. Clinical response was evaluated at EOS Visit as Cure: resolution of clinical signs/symptoms of pneumonia when compared with baseline; Failure: persistence/progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection; Unknown:extenuating circumstances precluding classification to 1 of the above.</description>
        <time_frame>EOS (7-30 days after last dose)</time_frame>
        <population>mITT population included all ITT participants who received at least 1 dose of drug with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome in Participants With Baseline MRSA at EOS for mITT Population</title>
          <description>Clinical response was based primarily on global assessment of clinical presentation of participant made by investigator at evaluation timepoint. Clinical response was evaluated at EOS Visit as Cure: resolution of clinical signs/symptoms of pneumonia when compared with baseline; Failure: persistence/progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection; Unknown:extenuating circumstances precluding classification to 1 of the above.</description>
          <population>mITT population included all ITT participants who received at least 1 dose of drug with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Missing (excluded from analysis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome in Participants With Baseline MRSA at End of Treatment (EOT) for PP Population</title>
        <description>Clinical response evaluated at EOT visit as Cure:resolution of clinical sign/symptoms of pneumonia when compared with baseline;Improvement: in 2 or more clinical sign/symptoms of pneumonia when compared with baseline,improvement/lack of progression of all chest X-ray abnormalities,Failure: persistence/ progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection;Unknown: extenuating circumstances precluding classification to 1 of above.</description>
        <time_frame>EOT (within 72 hours of last dose)</time_frame>
        <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome in Participants With Baseline MRSA at End of Treatment (EOT) for PP Population</title>
          <description>Clinical response evaluated at EOT visit as Cure:resolution of clinical sign/symptoms of pneumonia when compared with baseline;Improvement: in 2 or more clinical sign/symptoms of pneumonia when compared with baseline,improvement/lack of progression of all chest X-ray abnormalities,Failure: persistence/ progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection;Unknown: extenuating circumstances precluding classification to 1 of above.</description>
          <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Missing (excluded from analysis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome in Participants With Baseline MRSA at EOT for mITT Population</title>
        <description>Clinical response evaluated at EOT visit as Cure:resolution of clinical sign/symptoms of pneumonia when compared with baseline;Improvement: in 2 or more clinical sign/symptoms of pneumonia when compared with baseline,improvement/lack of progression of all chest X-ray abnormalities,Failure: persistence/ progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection;Unknown: extenuating circumstances precluding classification to 1 of above.</description>
        <time_frame>EOT (within 72 hours of last dose)</time_frame>
        <population>mITT population included all ITT participants who received at least 1 dose of drug with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome in Participants With Baseline MRSA at EOT for mITT Population</title>
          <description>Clinical response evaluated at EOT visit as Cure:resolution of clinical sign/symptoms of pneumonia when compared with baseline;Improvement: in 2 or more clinical sign/symptoms of pneumonia when compared with baseline,improvement/lack of progression of all chest X-ray abnormalities,Failure: persistence/ progression of baseline signs/symptoms of pneumonia or baseline radiographic abnormalities after atleast 2 days of treatment; development of new pulmonary/extrapulmonary clinical findings consistent with active infection;Unknown: extenuating circumstances precluding classification to 1 of above.</description>
          <population>mITT population included all ITT participants who received at least 1 dose of drug with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/Missing (excluded from analysis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome in Participants With Baseline MRSA at EOS for PP Population</title>
        <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
        <time_frame>EOS (7-30 days after last dose)</time_frame>
        <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome in Participants With Baseline MRSA at EOS for PP Population</title>
          <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
          <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MRSA Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed MRSA Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRSA Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRSA Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed MRSA Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing/Indeterminate (excluded from analysis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome in Participants With Baseline MRSA at EOS for mITT Population</title>
        <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
        <time_frame>EOS (7-30 days after last dose)</time_frame>
        <population>mITT population included all ITT participants (who received at least 1 dose of drug) with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome in Participants With Baseline MRSA at EOS for mITT Population</title>
          <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
          <population>mITT population included all ITT participants (who received at least 1 dose of drug) with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MRSA Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed MRSA Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRSA Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRSA Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed MRSA Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing/Indeterminate (excluded from analysis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome in Participants With Baseline MRSA at EOT for PP Population</title>
        <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
        <time_frame>EOT (within 72 hours of last dose)</time_frame>
        <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome in Participants With Baseline MRSA at EOT for PP Population</title>
          <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
          <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MRSA Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed MRSA Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRSA Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed MRSA Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing/Indeterminate (excluded from analysis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome in Participants With Baseline MRSA at EOT for mITT Population</title>
        <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
        <time_frame>EOT (within 72 hours of last dose)</time_frame>
        <population>mITT population included all ITT participants (who received at least 1 dose of drug) with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome in Participants With Baseline MRSA at EOT for mITT Population</title>
          <description>Microbiological response assessed at participant level.Eradication:baseline isolate not present in repeat culture from original infection site;Presumed Eradication:clinical response of cure precluded availability of specimen for culture;Persistence:baseline isolate present in repeat culture;Presumed Persistence:culture data not available for participant with clinical response of failure;Superinfection:culture from primary infection site had new pathogen not identified as baseline isolate and clinical response was failure;Indeterminate:any participant who cannot be classified into any of above.</description>
          <population>mITT population included all ITT participants (who received at least 1 dose of drug) with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MRSA Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed MRSA Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRSA Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed MRSA Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing/Indeterminate (excluded from analysis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Signs and Symptoms at EOS for PP Population</title>
        <description>Participant’s clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
        <time_frame>EOS (7-30 days after last dose)</time_frame>
        <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Signs and Symptoms at EOS for PP Population</title>
          <description>Participant’s clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
          <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decreased Breath Sounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoxia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Consolidation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rales</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachypnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills/Rigors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleuritic Chest Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Purulent Sputum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Signs and Symptoms at EOS for mITT Population</title>
        <description>Participant’s clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
        <time_frame>EOS (7-30 days after last dose)</time_frame>
        <population>mITT population included all ITT participants who received at least 1 dose of drug with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Signs and Symptoms at EOS for mITT Population</title>
          <description>Participant’s clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
          <population>mITT population included all ITT participants who received at least 1 dose of drug with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decreased Breath Sounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoxia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Consolidation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rales</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachypnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills/Rigors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleuritic Chest Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Purulent Sputum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Signs and Symptoms at EOT for PP Population</title>
        <description>Participant’s clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
        <time_frame>EOT (within 72 hours of last dose)</time_frame>
        <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Signs and Symptoms at EOT for PP Population</title>
          <description>Participant’s clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
          <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decreased Breath Sounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoxia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Consolidation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rales</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachypnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills/Rigors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleuritic Chest Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Purulent Sputum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Signs and Symptoms at EOT for mITT Population</title>
        <description>Participant’s clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
        <time_frame>EOT (within 72 hours of last dose)</time_frame>
        <population>mITT population included all ITT participants who received at least 1 dose of drug with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Signs and Symptoms at EOT for mITT Population</title>
          <description>Participant’s clinical evaluation of signs and symptoms were based on global assessment by investigator at specific timepoints. Signs and symptoms (mild to severe) of nosocomial pneumonia included cough; production of purulent sputum or change in character of sputum;auscultatory findings on pulmonary examination of rales and/or pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); and dyspnea, tachypnea, or hypoxemia with PaO2 &lt;60 mmHg or worsening gas exchange or increased oxygen requirements; pleuritic chest pain; chills/rigors; and decreased breath sounds.</description>
          <population>mITT population included all ITT participants who received at least 1 dose of drug with a diagnosis of nosocomial pneumonia caused by proven MRSA and had an observed outcome for that visit unless already declared a failure prior to that visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decreased Breath Sounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoxia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Consolidation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rales</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachypnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills/Rigors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pleuritic Chest Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Purulent Sputum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Status Estimated by Kaplan-Meier Analysis for PP Population</title>
        <description>For each participant, time to death was estimated from baseline to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose. The distribution of survival was estimated for the treatment groups using the Kaplan-Meier, product-limit method and compared between the treatment groups using the log rank statistic.</description>
        <time_frame>From baseline until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose.</time_frame>
        <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Status Estimated by Kaplan-Meier Analysis for PP Population</title>
          <description>For each participant, time to death was estimated from baseline to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose. The distribution of survival was estimated for the treatment groups using the Kaplan-Meier, product-limit method and compared between the treatment groups using the log rank statistic.</description>
          <population>PP population included all mITT participants who satisfied all critical inclusion/exclusion criteria,had adequate dosing of drug (defined as 5 full days for success or 2 full days of treatment for participants whose clinical outcome was considered failure)and had observed outcome for that visit unless already declared failure prior to that visit.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.196" spread="1.684"/>
                    <measurement group_id="O2" value="57.191" spread="1.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical comparison of survival analysis was performed.Log rank method was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9344</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Status Estimated by Kaplan-Meier Analysis for mITT Population</title>
        <description>For each participant, time to death was estimated from baseline to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose. The distribution of survival was estimated for the treatment groups using the Kaplan-Meier, product-limit method and compared between the treatment groups using the log rank statistic.</description>
        <time_frame>From baseline until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose.</time_frame>
        <population>mITT population included all ITT participants (who received at least 1 dose of drug) with a diagnosis of nosocomial pneumonia caused by proven MRSA.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Status Estimated by Kaplan-Meier Analysis for mITT Population</title>
          <description>For each participant, time to death was estimated from baseline to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose. The distribution of survival was estimated for the treatment groups using the Kaplan-Meier, product-limit method and compared between the treatment groups using the log rank statistic.</description>
          <population>mITT population included all ITT participants (who received at least 1 dose of drug) with a diagnosis of nosocomial pneumonia caused by proven MRSA.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.185" spread="1.605"/>
                    <measurement group_id="O2" value="57.072" spread="1.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical comparison of survival analysis was performed.Log rank method was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5985</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Status Estimated by Kaplan-Meier Analysis for ITT Population</title>
        <description>For each participant, time to death was estimated from baseline to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose. The distribution of survival was estimated for the treatment groups using the Kaplan-Meier, product-limit method and compared between the treatment groups using the log rank statistic.</description>
        <time_frame>From baseline until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose.</time_frame>
        <population>ITT population included all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Linezolid</title>
            <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Status Estimated by Kaplan-Meier Analysis for ITT Population</title>
          <description>For each participant, time to death was estimated from baseline to date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 days after last dose. The distribution of survival was estimated for the treatment groups using the Kaplan-Meier, product-limit method and compared between the treatment groups using the log rank statistic.</description>
          <population>ITT population included all participants who received at least one dose of study medication.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="597"/>
                <count group_id="O2" value="587"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.590" spread="1.511"/>
                    <measurement group_id="O2" value="55.369" spread="1.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical comparison of survival analysis was performed.Log rank method was used to calculate p-value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8590</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Linezolid</title>
          <description>Linezolid intravenous (IV) approximately every 12 hours (twice daily) at a dose of 600 milligrams (mg) infused over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
        </group>
        <group group_id="E2">
          <title>Vancomycin</title>
          <description>Vancomycin IV approximately every 12 hours (twice daily) at a dose of 30 mg/kg/day in 2 divided doses (15 mg/kg/dose) over a period of 60-120 minutes for 7 to 14 days except in cases of documented bacteremia where it could be extended to 21 days based upon investigator’s discretion.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Electromechanical dissociation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Intestinal dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Mesenteric vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Multi-organ disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Acinetobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Fungal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Failure to anastomose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tracheostomy malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ureteric cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Subdural hygroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Brain hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dependence on respirator</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Organising pneumon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tracheal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="348" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="381" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypoprothrombinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Postural orthostatic tachycardia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Diabetes insipidus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Corneal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pupillary reflex impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pupils unequal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastric hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lip ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Perianal erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Implant site effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Infusion site oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Infusion site phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Infusion site thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Multi-organ disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Puncture site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cytolytic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bacterial disease carrier</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Candiduria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Citrobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Enterobacter pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Fungal cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Fungal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Infectious disease carrier</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Infusion site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Infusion site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Mastitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pancreatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pleural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia escherichia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory moniliasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Stenotrophomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tracheostomy infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Wound infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Wound infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Anal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Endotracheal intubation complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Eschar</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Feeding tube complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haematuria traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hepatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Mechanical ventilation complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post concussion syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post procedural oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post-thoracotomy pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pulmonary radiation injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tracheostomy malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Acid base balance abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Antibiotic resistant Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood chloride decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Carbon dioxide increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Chest X-ray abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Clostridium test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Coagulation time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Fungal test positive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Gastric occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pedal pulse decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Prothrombin level decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pulse abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Radial pulse decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Reticulocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Spirometry abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Urine sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Influenza virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cell death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Electrolyte depletion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyperlactacidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Iron overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Metabolic alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Convulsions local</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Neuromuscular blockade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Paralysis flaccid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Radial nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Penile discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Penile swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Scrotal swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Testicular torsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Vulvovaginal burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute lung injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dependence on respirator</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Increased bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pleurocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous tension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pulmonary vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Leukocytoclastic vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Penile ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Plantar erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Rash papulosquamous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Red man syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Skin maceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="587"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="587"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>EOS visit window of 15-21 days after last dose as specified in protocol was expanded during blinded evaluability assessments and prior to database lock and unblinding to 7-30 days after last dose in order to better fit the actual study visit days.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

